Key Market Indicator:
Ad-hoc news is mandatory information from listed companies that must be made available to investors. Depending on the occasion and content of the news, it can have an impact on the share price. The newsfeed covers a wide range of topics relevant to investor relations and is recommended as an important source of information before making an investment decision.
CH0106213793
Fri, 30.06.2023       Spexis AG
CH0106213793

Spexis announces engagement with Maxim Group LLC as M&A advisor to support evaluation of strategic transactions Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, June 30, 2023   Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that it has engaged Maxim  [ … ]
Technical analysis
To the publication
Mon, 26.06.2023       Spexis AG
CH0106213793

Ad hoc announcement pursuant to Art. 53 LR     Allschwil, Switzerland, June 26, 2023 Spexis Annual General Meeting 2023 Spexis AG (SIX: SPEX) today announced that its shareholders approved all proposals of the Board of Directors at the 26th Annual General Meeting (AGM) with a significant majority. The represented percent of the company's share [ … ]
Technical analysis
To the publication
Mon, 26.06.2023       Spexis AG
CH0106213793

Ad hoc announcement pursuant to Art. 53 LR     Allschwil, Switzerland, June 26, 2023 Spexis Annual General Meeting 2023 Spexis AG (SIX: SPEX) today announced that its shareholders approved all proposals of the Board of Directors at the 26th Annual General Meeting (AGM) with a significant majority. The represented percent of the company's share [ … ]
Technical analysis
To the publication
Tue, 30.05.2023       Spexis AG
CH0106213793

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, May 30, 2023   Spexis provides business update and announces financial results for the full year 2022   USD 4.5 million capital commitment from SPRIM Global Investments to enable initiation of ColiFin® COPILOT study; first patient dosing expected in mid-2023 Reported solid saf [ … ]
Technical analysis
To the publication
Tue, 30.05.2023       Spexis AG
CH0106213793

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, May 30, 2023   Spexis provides business update and announces financial results for the full year 2022   USD 4.5 million capital commitment from SPRIM Global Investments to enable initiation of ColiFin® COPILOT study; first patient dosing expected in mid-2023 Reported solid saf [ … ]
Technical analysis
To the publication
Fri, 28.04.2023       Spexis AG
CH0106213793

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, April 28, 2023 Spexis has received temporary approval of an extension until 31 of May 2023 for the disclosure obligation in connection with the publication and the filing of the annual report 2022.   Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on ra [ … ]
Technical analysis
To the publication
Fri, 28.04.2023       Spexis AG
CH0106213793

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, April 28, 2023 Spexis has received temporary approval of an extension until 31 of May 2023 for the disclosure obligation in connection with the publication and the filing of the annual report 2022.   Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on ra [ … ]
Technical analysis
To the publication
Tue, 18.04.2023       Spexis AG
CH0106213793

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, April 18, 2023 Spexis announces closing of capital commitment of USD 4.5 million from SPRIM Global Investments (SGI) to enable initiation of ColiFin® Phase 3 study   Funding to enable immediate initiation of the COPILOT study, the first of two Phase 3 ColiFin® studies; first-pat [ … ]
Technical analysis
To the publication
Tue, 18.04.2023       Spexis AG
CH0106213793

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, April 18, 2023 Spexis announces closing of capital commitment of USD 4.5 million from SPRIM Global Investments (SGI) to enable initiation of ColiFin® Phase 3 study   Funding to enable immediate initiation of the COPILOT study, the first of two Phase 3 ColiFin® studies; first-pat [ … ]
Technical analysis
To the publication
Wed, 08.02.2023       Spexis AG
CH0106213793

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, February 8, 2023   Spexis and SPRIM Global Investments (SGI) Announce Plans for Clinical Trial Partnership to Fund up to Half of the Projected Phase 3 Clinical Development Costs of ColiFin® SGI debt facility to provide Spexis up to half of the projected ColiFin® Phase 3 developm [ … ]
Technical analysis
To the publication

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

Legend/Explanation
The newswire feed is updated several times a day. To make sure you don't miss any news, please check back here often. If you are curious about a headline or want to find out more about a publication, click on it to go to the preview and click again to go to the full news item.
Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Saturday, 06.07.2024, Calendar Week 27, 188th day of the year, 178 days remaining until EoY.